Histone Deacetylase (HDAC) Inhibitors. In non-small cell lung cancer (NSCLC), chidamide, an HDAC inhibitor, inhibited c-MET expression by decreasing the m6A methylation of c-MET, potentially through targeting WTAP and METTL3 [36]. This evidence concerns the gene METTL3 and non-small cell lung carcinoma.